Der Biologika-Auftragshersteller verzeichnet solides Umsatzplus von 9,6% im Geschäftsjahr 2024 trotz Kurskorrektur und erwartet eine Wachstumssteigerung für 2025. Die WuXi Biologics-Aktie ...

WuXi Biologics differentiates itself from other well-established global contract development and manufacturing organizations, with its "follow-and-win the molecule" and "global dual-sourcing ...

Jefferies analyst Cui Cui maintained a Buy rating on Wuxi Biologics (Cayman) (WXIBF – Research Report) today and set a price target of ...

CORRECTION: WuXi Biologics has disputed a claim by WBJ construction has stopped at its Worcester facility. An earlier version of this article incorrectly conflated details involving WuXi Biologics ...

WuXi Biologics differentiates itself from other well-established global contract development and manufacturing organizations with its "follow and win the molecule" and global dual sourcing strategies.

WuXi Biologics (2269.HK), a leading global CRDMO, has once again earned top recognition at the 2025 CDMO Leadership Awards, ...

Shortly after WuXi AppTec provided an upbeat outlook for 2025, several other WuXi sibling companies are coming forward with ...

To address the challenges in producing these biomolecules, WuXi Biologics has introduced the EffiX™ platform, which enables the development and manufacturing of microbial-derived biologics with ...

WuXi Biologics has launched the E coli expression system, EffiX, designed to enhance the production of recombinant proteins and plasmid DNA (pDNA). The worldwide market for microbial-derived ...

Leader in Green CRDMO to drive innovation for a healthier future SHANGHAI, March 10, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development ...